One of our members is setting up a project investigating the genetic determinants of therapeutic response in Non-Small Cell Lung Cancer and is looking for potential collaborators with an interest in cancer genomics and therapeutic responses.
Numerous cancer genome resequencing projects have been conducted to better understand the genetic causes of cancer. However, 3’UTR of genes has been largely ignored in the search of novel genetic variants associated with oncogenesis and acquired resistance to therapy. Discovering mechanisms of acquired resistance is vital in finding novel therapies and improve patient outcomes.
It has been shown that miRNAs play role in tumorigenesis by regulating expression of proto-oncogenes and tumour suppressor genes. These small non-coding miRNAs are known to bind to imperfect complementary sequences in the 3’UTR of target mRNAs. Genetic variants in 3’UTR regions might destroy or create a miRNA binding site leading to changes in gene expression. Hence, 3’UTR variation in cancer genes has a potential to affect cancer susceptibility, therapeutic response and disease outcome.
This project seeks to interrogate single nucleotide polymorphisms (SNPs) in miRNA binding sites in the 3’UTR of driver genes linked to non-small cell lung cancer (NSCLC) development as well as the genes associated with drug metabolism with the aim of identifying novel genetic determinants of response to tyrosine kinase inhibitors (TKIs).
Newly identified molecular biomarkers may be useful for future research of therapeutic strategies in NSCLC and would aid patient stratification for cancer treatment.
Do you have a project that you would like us to feature on our website? If so, please click here for our "Create A Collaboration" form.